Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Xena, you say "The stock structure arouses my greatest suspicion ..."
But what about the science behind Byrostatin? Any opinion on that?
I would have to say that is true of every stock I have owned that was waiting for an up listing or some sort of funding.
And yes, Insiders always have more info than retail.
But what evidence, to date, do you have of any insider price manipulation for personal or corporate gain with Neurotrope?
kld you write: “There is no clinical data to corroborate efficacy. Usually this outcome is what justifies a company's decision to advance or not. Everything is money.”
Ignoring the animal studies, very limited Phase 1 and compassionate use results consider what Dr. Alkon stated:
“(Bryostatin) is well positioned to virtually…take care of every major aspect of this disease. So it is multi modal, multi modal means that we can look at prevention, slowing down progression, and actual reversal of Alzheimer’s disease. Which is what is in our current Phase 2 trial.”
Phase2b results should answer all of your concerns one way or another.
In the BIO CEO Presentation I believe NTRP telegraphed their expectations for their upcoming P2b results. Dr. Alkon, in his comments, made a clear case for his decades of research into the mechanism and potential treatment of Alzheimer’s disease. In the end there was no equivocation, no doubts, that they expect success in their P2b trial.
doingmybest, any investor has to decide to either believe...or not the public statements a company is making. At this juncture I am choosing to believe what Drs. Wilke and Alkon have been telling us.
See my notes:
NTRP: 2/13/17 BIO CEO & Investor Conference
Dr. Wilke:
Minute 4:14: we are unique in that we are stating that we can regenerate synapses and synaptic networks. And by regenerating these synapses and synaptic networks we can actually reverse Alzheimer’s disease even in advanced patients.
Minute 4:29: we believe we have a uniquely regenerative mechanism that actually will show strong clinical benefit in our clinical trial which is different than just treating or preventing the formation of amyloid plaque.
Minute 5:18: we are pretty excited about our upcoming Phase 2 top line data in April 2017, as I said in moderate to severe AD patients, which we believe will be a pivotal inflection point for the company
Dr. Alkon:
Minute 17:54: I do want to say that Bryostatin is one of a platform of drugs that we have. It is our lead compound now because it has experience in the patient population and we know it’s well tolerated. But we have 40 or so other compounds some of which are even more potent and even more specific and have proprietary composition of matter protection which we can use for second and third generation of drugs.
Minute 23: (Bryostatin) is well positioned to virtually…take care of every major aspect of this disease. So it is multi modal, multi modal means that we can look at prevention, slowing down progression, and actual reversal of Alzheimer’s disease. Which is what is in our current Phase 2 trial.
Minute 25:45 (refer to Slide 40 – Bryostaten Compassionate Use Program: Severe Alzheimer’s Disease “No other reports have ever shown comparable benefits in such severely demented patients”) These are our compassionate use patients…we saw major reversal of disease that’s why we teed-up our Phase 2 trial in the way we did for severe (Alzheimer’s) patients to see reversal. To see not just a reduction in the rate of decline…but a flipping, a changing of the sign of what happens, for example, with the preferred metric of advanced Alzheimer’s disease, the Severe Impairment Battery.
https://www.veracast.com/webcasts/bio/ceoinvestor2017/18111483071.cfm
kld, I doubt anybody on this board has the scientific expertise to evaluate the biochemistry of Bryostatin and Dr. Alkons research.
Dr. Susanne Wilke, PhD, Chief Executive Officer of Neurotrope, in her presentation at the Noble Financial Capital on 1/30/17 did state:
“we are testing in late stage patients to make the point of a significant reversal (in AD). This treatment should be applicable to moderate to early stage to MCI (mild cognitive impairment) patients.”
So, the company is hypothesizing that success in late stage patients will translate into an early treatment for AD.
If Dr. Wilke is right then John Carroll, editor at END POINTS NEWS, in an article last week discussing the recent AD research failure at Lundbeck and problems at Axovant states what we are all hoping for with Neurotrope:
“If a developer can get through an R&D field littered with huge failures like solanezumab and bapineuzumab and make it to the market with a drug, the payoff would be worth billions in annual revenue.”
https://endpts.com/lundbeck-reads-last-rites-on-another-failed-phiii-alzheimers-program/
For those that might not be on Twitter and who would like to follow Twitter tweets about NTRP:
https://twitter.com/search?q=%24NTRP&src=ctag
kld, excellent post. With the NASDAQ listing I would expect more volatility and manipulation by hedge funds, short attack groups, and outright scammers.
By the way, only 65 people voted in that poll so far:
https://twitter.com/princetongb
Hanuman, Bigger Capital is an investment fund. As of November 2016 they claimed to own 1.5 million shares of NTRP.
This is a very interesting read:
One quote: "The FDA is DESPERATE to shuttle through any therapeutic that is showing disease modifying activity in AD. If Anavex (AVXL) can have multi-hundred million mkt cap so can NTRP. NTRP has the ear and eyes of the FDA, and back by reputable science and scientist."
http://biggercapital.squarespace.com/biggercapital-investment/2016/11/20/our-second-alzheimers-investment-neurotrope.html
Michael Bigger on Twitter responding to a question about Bryostatin super responders:
Michael Bigger ?@biggercapital 4h
4 hours ago
More
Michael Bigger Retweeted Kenneth Dreesen
I got confirmation that the drug was given to only four patients and the results shown are not"super responders" biased. $NTRP
Michael Bigger added,
Kenneth Dreesen @Dreesenkl
@biggercapital Interesting. Hope these aren't flukes. AVXL also has some "superresponders."
1 reply
4 retweets
4 likes
Wow, what a day. Up $2.92/share!
Major New Seeking Alpha article:
http://seekingalpha.com/article/4046795-neurotrope-bioscience-upcoming-alzheimers-trial-results-may-propel-share-price
We reckless abandon I will take a stab at answering your question blu 1.
You write “Assuming bryostatin-1 becomes the new SOC and does indeed reverse Alzheimers Disease, ballpark, what would share price of NTRP eventually be?”
I believe the first question to ask is how much of a run-up in share price will there be as we approach the April P2b data release.
Both Dr. Alkon, President and Chief Scientific Officer, and Dr. Wilke, CEO, have made very positive statements at investor conferences and in the Benzinga articles in the last two weeks. So there are positive expectations among what is still a very small group of stockholders (maybe 500 or so).
Publicity about NTRP has been limited and within the on-line investor community. Bloomberg, Rueters, and the mainstream media have not picked-up on it yet.
The other side of the equation is that the P2b study is taking place at 29 locations. Anecdotal leaks from the researchers, staff, family member of the participants, etc. are a possibility and could affect the share price.
SEE: A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease https://clinicaltrials.gov/ct2/show/NCT02431468?term=Bryostatin-1&rank=8
Personally, I am watching trading volume, chart metrics, twitter posts, and company info.
I believe that lacking negative reports or positive rumors, the stock price could move up to the $35 to $50 range just prior to the data release…just my opinion.
Then if the data is as positive as the company is implying all bets are off and the sky is the limit.
New recommendation by InsiderFinancial.com
Neurotrope Inc (OTCMKTS:NTRP) Remains A Top Pick Ahead Of Data
By Chris Sandburg on Thursday, 16 Feb 2017
Back in December 2016, we looked at Neurotrope Inc (OTCMKTS:NTRP) as part of this coverage. We noted that the company had just taken a hit on the announcing of a private placement, and that (as we see so often in biotech) the market response to these sort of events can warrant a speculative entry ahead of the capital being put to use, and driving growth.
We highlighted a key catalyst, the releasing of data from the company’s lead trial, as an event to watch, and noted that it was set to hit press at some point late first quarter or early second quarter 2017.
Since our coverage, the company reverse split, and post split, has struggled to maintain positive sentiment. This struggle doesn’t affect our thesis, however. Again, we think this represents an opportunity to get in ahead of the data release, and that once the data hits, markets will be rushing to pick up a piece of the action ahead of a pivotal trial initiation.
What makes us feel so strongly about this study? The science.
Sometimes in biotechnology, and especially at this end of the space, you’ve got to ignore everything else, and have faith that the science underpinning a particular drug or program of drugs will win out. If the science is sound, more often than not the drug will overcome any extraneous inputs and succeed in getting to market. Not always, of course, but at a far higher proportion that can be said for a company with great management, great capital structure but poor science.
And with this one, the science is very strong. Alzheimer’s is an incredibly tough condition to treat, and many companies have spent billions on what have turned out to be failed development programs. Most of these, however, have targeted the build up of what’s called Tau, and what’s called amyloid plaque. Basically, there seems to be a correlation between the build up of these two elements and the severity of the symptoms. That’s the logic behind the many (failed) mechanisms of action that have been investigated over the past thirty or more years. More recently, however, some companies are investigating alternative MOAs, and Neurotrope is one such company.
It’s looking at a protein called PKC. In patients with Alzheimer’s, PKC has been shown to correlate with severity, as well as plaque and Tau buildup. The correlation, Neurotrope believes, is rooted in PKC’s role in synapse formation. Synapse formation has been shown to correlate with an improvement in the symptoms of many neurodegenerative conditions (mainly animal models). This is a key point – while synapse degradation, and Tau and amyloid buildup, have been shown to correlate with worsening symptoms, only synapse reformation has been shown to correlate with improving symptoms. Neurotrope’s lead asset, called Bryostatin, blocks a mutated gene that prevents PKC expression, and activates a gene that promotes PKC expression. In turn, it promotes synaptic formation, and – if the above mentioned correlation is to be trusted – this formation should result in improved symptoms.
A host of primary and secondary endpoints are setup to measure and identify any improvement in symptoms in patients treated with Bryostatin when compared to a placebo arm in the ongoing phase II, and it’s this data that is set to hit press near term. At the time of our previous coverage (and as mentioned above) end first quarter/early second was highlighted as a target un-blinding and topline period. At the BIO Conference, management just refined this to end April.
The thing to takeaway here is that this company is taking a fresh approach to an indication that the industry’s biggest names have wasted billions of dollars on, and this is bringing with it a (perhaps reasonable) degree of skepticism. Reasonable, sure, but totally justified – in our opinion, and based on the science, probably not.
Cash, as ever, will be an issue going forward. The company needs a raise or a partnership if it’s going to fund a phase III. With that said, if the data reads out as positive, we expect Neurotrope to have its pick of the big pharma litter as a partner.
https://www.insiderfinancial.com/neurotrope-inc-otcmktsntrp-remains-a-top-pick-ahead-of-data/119645/
Thanks for clarifying that F1ash.
I hope AVXL is as successful as I believe NTRP will be.
I also believe that NTRP will be the first company in the history of AD research to report a treatment that actually works. When it does it is going to become the industry leader and dominate news on AD research and cure.
The Trump administration has indicated it wants less oversight and more fast track approval of promising drugs and it just might turn out that with positive Phase 2b results Bryostatin will be an early candidate for some kind of new FDA expedited process.
The potential societal and fiscal benefits will likely bring pressure on the FDA to act.
Alzheimer’s is a major drain on Medicare, Medicaid, and Social Security Disability budgets, (not to mention long suffering families). A successful treatment will change the math on all of those programs and save the US taxpayer possibly trillions.
bUrRpPPP!, I notice that in Taylor Cox’s, Benzinga article AVXL is not mentioned.
Dr. Alkon of Neurotrope states:
"There is a long line of trials, all going after amyloid in different ways that never have worked. What we're trying to say is, look at the elephant in the room. The elephant in the room is look at the loss of wiring in the brain."
My question is does AVXL fall into the treating amyloid deposits hypothesis camp or not?
If it does, according to Dr.Alkon, the implications are not good.
runncoach you make an excellent point.
You write: "Actually in a perfect world bryostatin would protect from synapses failure in the first place so there would be no need for additional drugs. Multi modal as Dr Alkon pointed out."
The implication should be obvious, other companies in the field may have a difficult time raising additional funding as money flows to a proven treatment.
"Eli Lilly, Biogen, and Neurotrope Fight to Find Viable Treatment for Alzheimer’s Disease"
This article is from December 2016 (I am not sure if it has been posted on the board before). But we now know how Eli Lilly's Solanezumab study crashed and burned:
http://thebioconnection.com/eli-lilly-biogen-neurotrope-fight-find-viable-treatment-alzheimers-disease/
NTRP, in my opinion, has a favorable risk reward ratio:
Dr. Alkon, his former team at the Blanchette Rockefeller Neurosciences Institute, and other researchers in the field have identified the detailed chemical pathways and brain chemistry that they believe describes Bryostatin’s effectiveness.
Bryostatin has shown efficacy in animal studies, in a very limited number of compassionate use patients, and in a short time frame will release the results of their Phase 2 double blinded study. Safety data from previous unsuccessful cancer studies on over 1500 patients shows Bryostatin to be well tolerated. Bryostatin was recently synthesized by a research team at Stanford and licensed by Neurotrope. Financially, NTRP is well positioned, and with the exercise of outstanding warrants will raise another $50 million. NASDAQ up-listing is around the corner.
Also consider that the Trump administration has indicated it wants less oversight and more fast track approval of promising drugs and it just might turn out that with positive Phase 2b results Bryostatin will be an early candidate for some kind of new FDA expedited process.
The potential societal and fiscal benefits of a successful treatment will likely bring pressure on the FDA to act.
Alzheimer’s is a major drain on Medicare, Medicaid, and Social Security Disability budgets. A successful treatment will change the math on all of those programs.
Maple Tree, the following press release is technical, but in it NTRP lays out their roadmap for treating neurodegenerative diseases:
Neurotrope announces that a new study published in the Journal of Biological Chemistry shows that Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes
PR NewswireJune 23, 2016
NEWARK, N.J., June 23, 2016 /PRNewswire/ -- Neurotrope, Inc. (NTRP) today announced that a study published in the Journal of Biological Chemistry shows that its lead Alzheimer's drug, Bryostatin, licensed from the Blanchette Rockefeller Neurosciences Institute (BRNI), increases the levels of the synaptic scaffolding protein PSD-95, and induces the movement of phosphorylated PSD-95 to the neuronal membranes.
The study, conducted within the BRNI basic research programs, showed that Bryostatin induced activation of PKC epsilon increased synaptic number, pre-synaptic vesicle density, and clusters of PSD-95. It is known that either Aß or tau, both toxic proteins in Alzheimer's disease brains, can induce reduction of PSD-95 in excitatory synapses in hippocampus. Furthermore, this PSD-95 reduction continues to occur as the Alzheimer's pathologies advance. A Phase 2b clinical trial funded by Neurotrope Bioscience, Inc., Neurotrope, Inc.'s wholly-owned subsidiary, is underway to test the efficacy of Bryostatin for the treatment of the causes and progression of Alzheimer's disease.
The new study, demonstrating for the first time a close relationship between PKC epsilon and its downstream target, PSD-95, is entitled "PKC epsilon Promotes Synaptogenesis through Membrane accumulation of the Postsynaptic Density Protein PSD-95" with lead author, Dr. Abhik Sen, as published online in the Journal of Biological Chemistry, June 21, 2016. "Dr. Sen, together with Dr. Tom Nelson, continue to reveal important new insights into the processes of brain degeneration and regeneration," said Dr. Dan Alkon, Scientific Director of BRNI.
"Our studies consistently demonstrate that the synaptogenic growth factors such as BDNF, NGF, IGF, etc. are increased by bryostatin-induced activation of PKC epsilon. Bryostatin has the ability to regenerate the brain wiring lost in pre-clinical disease models and entirely restore memory capacity due to many causes of neurodegeneration such as Alzheimer's, Fragile X, and TBI." Dr. Alkon went on to say, "This latest article provides major new evidence that BRNI is developing and Neurotrope is clinically testing bryostatin as a potential "universal" therapeutic for neurodegeneration in the brain, however it arises, even due to disease genes as distinct as Fragile X, ApoE, and Presenilin – as recently described in a BRNI review article published in the June 2015 edition of Trends in Pharmacological Sciences (Vol. 36 No. 6. http://dx.doi.org/10.1016/j.tips.2015.04.004)."
Neurotrope, Inc. is currently conducting a Phase 2B clinical trial to validate PKC epsilon activation therapy in Alzheimer's disease, a potential paradigm shift in the field, for which Bryostatin already has received Orphan Drug status from the FDA for Fragile X Syndrome (FRX).
http://finance.yahoo.com/news/neurotrope-announces-study-published-journal-123000681.html
The excerpts below from today’s Bloomberg article mirrors what Dr. Alkon of NTRP said in his BIO CEO presentation yesterday. Essentially, treating amyloid deposits is treating one of the symptoms of AD not the underlying cause and will not be successful.
Merck Stops Alzheimer's Study After `No Chance’ of Benefit
“It’s very disappointing, once again,” said David Knopman, a professor of neurology at the Mayo Clinic in Rochester, Minnesota…
Merck’s drug and others target a plaque, called amyloid, thought to be a cause of the disease. While more such treatments are in development from companies including Biogen Inc. and Roche Holding AG, many researchers now believe that administering drugs after amyloid has built up in the brain may be too late.
“There is mounting evidence -- of which this is another piece -- that removing amyloid once people have established dementia is closing the barn door after the cows have left,” Knopman said.
https://www.bloomberg.com/news/articles/2017-02-14/merck-stops-alzheimer-s-study-after-no-chance-of-effectiveness
Zena, I think you are missing the point when you write:
“The share structure is such that insiders have the power to beat the snot out of retail. The liquidity is so low that market has no influence on share price.”
I believe the run up from $6.50 to $16.00 in the last month or so is precisely because a small group of retail investors who are following NTRP developments have been buying the stock.
The low float and lack of sellers, insider or retail, is constraining liquidly and thus buyers have been in charge.
This is all driven by the expectation of positive P2b results in the next 10 weeks. Also, with a NASDAQ up listing, possibly by the end of this month, options should be available. The stock then might be attractive to funds that have internal restraints on OTC investing.
If results meet positive expectations then retail buying will go into overdrive.
At some point, in the very near future, recent developments at Neurotrope will explode into the popular press.
In yesterday’s BIO CEO Presentation NTRP telegraphed their expectations for their upcoming P2b results. Dr. Alkon, in his comments, made a clear case for his decades of research into the mechanism and potential treatment of Alzheimer’s disease.
In the end there was no equivocation, no doubts, that they expect success in their P2b trial, with results by the end of April.
The implication for Dr. Alkon and for Neurotrope is vast. The first successful Alzheimer’s disease treatment, in the history of medicine, would transform Neurotrope into a Biotech phenomenon and probably put Dr. Alkon in line for the Noble Prize.
Alzheimer’s and other neurotrophic diseases are a scourge of humankind and of an ageing population.
We wish Neurotrope every success.
NTRP: 2/13/17 BIO CEO & Investor Conference
My notes
Dr. Wilke:
Minute 4:14: we are unique in that we are stating that we can regenerate synapses and synaptic networks. And by regenerating these synapses and synaptic networks we can actually reverse Alzheimer’s disease even in advanced patients.
Minute 4:29: we believe we have a uniquely regenerative mechanism that actually will show strong clinical benefit in our clinical trial which is different than just treating or preventing the formation of amyloid plaque.
Minute 5:18: we are pretty excited about our upcoming Phase 2 top line data in April 2017, as I said in moderate to severe AD patients, which we believe will be a pivotal inflection point for the company.
Dr. Alkon:
Minute 17:54: I do want to say that Bryostatin is one of a platform of drugs that we have. It is our lead compound now because it has experience in the patient population and we know it’s well tolerated. But we have 40 or so other compounds some of which are even more potent and even more specific and have proprietary composition of matter protection which we can use for second and third generation of drugs.
Minute 23: (Bryostatin) is well positioned to virtually…take care of every major aspect of this disease. So it is multi modal, multi modal means that we can look at prevention, slowing down progression, and actual reversal of Alzheimer’s disease. Which is what is in our current Phase 2 trial.
Minute 25:45 (refer to Slide 40 – Bryostaten Compassionate Use Program: Severe Alzheimer’s Disease “No other reports have ever shown comparable benefits in such severely demented patients”) These are our compassionate use patients…we saw major reversal of disease that’s why we teed-up our Phase 2 trial in the way we did for severe (Alzheimer’s) patients to see reversal. To see not just a reduction in the rate of decline…but a flipping, a changing of the sign of what happens, for example, with the preferred metric of advanced Alzheimer’s disease, the Severe Impairment Battery.
https://www.veracast.com/webcasts/bio/ceoinvestor2017/18111483071.cfm
Concerning the share structure of NTRP:
What is obvious is the extremely low float.
Based on the information below I think the float is in the neighborhood of only 4 to 5 million shares.
With a cursory review I come up with approximately 12.5 million to 13 million fully diluted authorized shares (includes warrants).
Outstanding shares are somewhere between 6.8 million and 8 million. (The OTC website shows 6.781 million but when I checked with the company last week I was told around 8 million). The difference probably has to due with the actual number of Series A, C warrants that may have already been exercised since the end of the year. Series E and F are not yet exercisable. I could not find the status of the Placement Agent Warrants
The follow account is from Page 45 of the S1 dated Dec. 16th 2016: (All figures are prior the 32 to 1 reverse split. The figures in parentheses are the total after the reverse that I have calculated).
http://archive.fast-edgar.com//20161219/AKAZG22DZZ22M2Z2229O22ZIDBINZB223682/#a_024
“As of December 7, 2016, we had 212,435,016 (6,638,594) shares of our common stock issued and outstanding held by approximately 425 stockholders of record. To date, we have not paid dividends on our common stock.
As of December 7, 2016, we also had the following securities outstanding:
• Series A Warrants to purchase 19,436,602 (607,393) shares of our common stock at an exercise price of $0.01 per share, with an expiration date five years from the date of issuance.
• Series C Warrants to purchase 19,436,602 (607,393) shares of our common stock at an exercise price of $0.01 per share, with an expiration date of five years from the date of issuance.
• Series E Warrants, which are contingent upon the exercise of the Series C Warrants, to purchase 26,234,940 (819,841) shares of our common stock at an exercise price of $1.00 (exercisable at $32.00) per share, with an expiration date that is five years from the date of the initial exercise of the Series C Warrants.
• Series F Warrants to purchase 122,517,500 (3,828,671) shares of our common stock at an exercise price of $0.40 (exercisable at $12.80), with an expiration date five years from the date of issuance.
• Placement agent warrants to purchase 3,618,802 (113,087) shares of our common stock at an exercise price of $0.01 per share.
• Placement agent warrants to purchase 12,251,750 (382,867) shares of our common stock which have an exercise price of $0.20 (exercisable at $6.40) share per share.”
There are 819,814 Series E warrants priced at $32.00 (post reverse split). These warrants appear not to have been registered so they are not exercisable. If and when exercised NTRP will receive $26.2 million.
There are a 3,828,671 Series F warrants priced at $12.80 (post reverse split). On Jan. 30th NTRP filed to register these warrants. (I am not sure of the effective date when they will be exercisable). If and when exercised NTRP will receive $49 million.
According to the company around 20% of the outstanding shares are held by insiders, also, funds and long term holders might have another 15 to 20% of the outstanding shares, (but their investment decisions could put those shares on the market at any time).
In my opinion, given the low float, it should be obvious that positive Phase 2b results will be highly accretive to the stock price.
Concerning the low float (my estimate is 4 to 5 million shares in the float), last week I was contacted by my Brokerage to lend my shares. The loan rate that was offered was an astounding 47%! That is an annualized rate payable daily based on the share price. (The rate also fluctuates daily).
Of course, the purpose was to make my shares available to short sellers so they could bet against the stock and knock down the share price.
But the loan rate, 47% at the time of the offer, has other implications. It suggests a significant demand among short sellers. It also suggests shorting where the party shorting the stock is desperately looking for shares to cover their short. If a naked short seller has not located a borrow to cover their short trade within 3 days they will need to purchase back the shares they have sold on the open market (or engage in illegal naked shorting). This buy in demand is probably what is driving up the loan rate.
With the extremely low float, and what may be institutional shorting, this stock has explosive potential, to the upside (or downside).
Neurotrope Bioscience to Present at the 19th Annual
BIO CEO & Investor Conference 2017
NEW YORK, February 7, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP / NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases including Alzheimer's disease, announces that Susanne Wilke PhD, Neurotrope’s Chief Executive Officer, and Dr. Daniel Alkon, President and Chief Scientific Officer, are scheduled to present at the 2017 BIO CEO & Investor Conference being held February 13-14, 2017 at the Waldorf Astoria Hotel in New York City.
The Company’s presentation will take place on Monday, February 13th, 2017 at 10:30am EST in the Conrad room during the conference's CNS/Neurological Track. In addition, any investors attending the conference that wish to meet with Neurotrope’s management can also contact our Director of Communications, Jeffrey Benison.
Neurotrope will announce topline efficacy results for its Phase 2, randomized, double blind, placebo controlled trial in 148 patients with moderate to severe Alzheimer's patients this coming April. The Company's lead drug, bryostatin-1, has demonstrated in animal models, efficacy for restorative synaptogenesis, prevention of neuronal death, and anti-amyloid, anti-tau metabolism via the activation of PKC epsilon. The restorative therapeutic potential of bryostatin-1 and bryostatin-like activators, may be fundamental to a number of neuro-degenerative pathways and neurologic indications including AD, Fragile X syndrome (FXS), stroke, traumatic brain injury (TBI), and depression.
A live and 90 day archived webcast of the presentation will be available at
https://www.veracast.com/webcasts/bio/ceoinvestor2017/18111483071.cfm
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded biotech companies. The conference’s mission is to support industry-wide success, and to present a broad and unbiased view of investment opportunities. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.
About Neurotrope
Neurotrope is at the forefront of developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's disease and other neurodegenerative diseases. The Company's world-class science is a paradigm shifting approach that treats some of the underlying causes of Alzheimer's disease.
The scientific basis of our treatment is activation of Protein Kinase C isozymes e and a by bryostatin, a natural product, which in mouse Alzheimer's disease models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.
Neurotrope is conducting a Phase 2 trial of bryostatin in the treatment of moderate to severe Alzheimer's disease, as well as preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Sydrome, three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome. Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.
My updated (in bold) notes of Susanne Wilke, PhD, Chief Executive Officer of Neurotrope, presentation at the Noble Financial Capital on 1/30/17:
Minute 8:25 "we are seeing remarkable results in reversal of Alzheimer's Disease"
Minute 10:41 "with this license we are able to synthesize Bryostatin in larger commercial quantities"
Minute 17:58 "we have compassionate use protocol results in Alzheimer patients that shows significant improvement in cognition and daily living..."
Minute 18:25: “we have Phase 2a completed which was a smaller Phase 2. We achieved our primary safety endpoint, we saw targeted engagement and we saw some limited cognitive enhancement in a short period of time.
Minute 26:42: “we are testing in late stage patients to make the point of a significant reversal (in AD). This treatment should be applicable to moderate to early stage to MCI (mild cognitive impairment) patients.
Top line results in April.
http://noble.mediasite.com/mediasite/Play/c54248f852db4353b8f007b16745782b1d
Southern Gal, ORIONS-Money-Stocks has discovered TRCH. They started posting about it late this afternoon. Lucky for us. Expect increased interest, upward price movement, and volatility. Check out their board.
http://investorshub.advfn.com/ORIONS-Money-Stocks-12753/
At this point the indications are good runncoach.
If Bryostatin performs in treating Alzheimer's "blockbuster drug"
will be too tame a term. Perhaps it will be the first "mega blockbuster".
Dr. Alkon's (President and Chief Scientific officer of NTRP) 2015 Sachs conference presentation:
(His presentation, in my mind, raises the question can Bryostatin, through its stimulation of the growth of synaptic connections, also be an intelligence enhancer? Obviously, the question to be answered is if synaptic growth correlates with IQ. See about 14 minutes into presentation.)
http://www.neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/Neurotrope_BioScience_files/MAH00004.MP4
TRCH Noble Conference Presentation 1/31/17
This is a comprehensive overview of where the company is at. Buying the stock at today's price you are getting the Oro Grande play at no cost:
http://noble.mediasite.com/mediasite/Play/a2a94ecd48ca4a058ec909a5731fdb5c1d
My notes of Susanne Wilke, PhD, Chief Executive Officer of Neurotrope, presentation at the Noble Financial Capital on 1/30/17:
Minute 8:25 "we are seeing remarkable results in reversal of Alzheimer's Disease"
Minute 10:41 "with this license we are able to synthesize Bryostatin in larger commercial quantities"
Minute 17:58 "we have compassionate use protocol results in Alzheimer patients that shows significant improvement in cognition and daily living..."
Top line results in April will be a make or break event for this company.
HANUMAN, this list should help you:
Daniel Alkon was a founder of NTRPD (not all of the patents on this list pertain to NTRPD)
http://www.patentsencyclopedia.com/inventor/daniel-l-alkon-bethesda-us-1/
Hudson Bay Capital Management has three quarters of a million shares and five million warrants:
http://ih.advfn.com/p.php?pid=nmona&article=73726426
Benzinga follow-up article...this is well written and more detail:
https://www.benzinga.com/general/biotech/17/01/8962220/taking-a-clinical-road-less-traveled-neurotrope-hopes-to-succeed-in-al?utm_source=dlvr.it&utm_medium=twitter
I first read about TRCH over at 321Energy last year and started accumulating it. They seem to have a decent handle on the Permian Basin and this company. It has been slow to develop but it looks like it is heating up.
http://www.321energy.com/index.php
Southern Gal, any idea that explains today's up move?
TNIB: Possible short squeeze?
According to iHub on 08/15/14 there were 5,336,000 TNIB shares short.
There are about 90,500,000 shares outstanding according to the company.
All shareholders will have to withdraw all of their shares from their Brokerage Account in connection with the mandatory surrender of TNIB share certificates in order to
receive the Cytocom, Inc. dividend. See the Sept. 9th Press Release: http://ih.advfn.com/p.php?pid=nmona&article=63523225
As it appears that most shareholders will want the dividend there is not going to be much of a float left in Brokerage accounts from which to borrow stock to short. Short positions could be called to cover if the stock is no longer available. Of course shorts are not dumb, so it is possible that most have already covered in the last 3 weeks.
From the Press Release:
"CYTOCOM INC. SPIN OUT
We have received numerous calls concerning the Cytocom Inc. dividend and below is additional information for shareholders.
Our shareholders will receive one common share of Cytocom Inc. for every one share of Company common stock held by such shareholders as of 5:00 p.m., Eastern Time, on September 30, 2014, which is the "record date" for the distribution.
However, to the extent that a shareholder of the Company sells a portion or all of that stockholder's shares of our common stock prior to the record date, such stockholder also will be pro-rata selling the right to receive common shares of Cytocom Inc. through the distribution.
To receive the Cytocom Inc. share dividend, all shareholders must surrender all existing share certificates to the Company's transfer agent. Shares in Street Name will need to be in the name of the shareholder when presented to the transfer agent for the dividend.
There is no electronic transfer so shareholders must obtain Company certificates in their name from their broker and present them to our transfer agent, Guardian Register & Transfer Inc.: 7951 South West 6th Street, Suite 216 Plantation, FL 33324, Tel: (954) 915-0105, Email: clientservices@guardiantransfer.net,
The below link will provide a sample letter to brokers that can be sent to your broker to convert your shares back into certificate form : http://www.tnibiotech.com/investor-relations/letter-of-instruction-to-broker
When shareholders present their Company share certificates to our transfer agent, our transfer agent will then send to each such shareholder proof of Cytocom Inc. common stock ownership, as of the record date. Cytocom Inc. shares will be kept in book entry until a Registration Statement on Form S-1 is declared effective by the Securities and Exchange Commission unless a shareholder requests differently. Once the transfer agent books the ownership of Cytocom Inc. common stock, as of September 30, 2014, the Company share certificates will be returned to the shareholder.
If you have any questions please do not hesitate to get in touch with either our transfer agent at elson@guardiantransfer.net or Kirsten Bartholomew at Kirsten.Bartholomew@tnibiotech.com."
Proof ChitownMike, what proof do you have that NWGC's PR's are fake as you state in your post????????
ChitownMike: you write "Fake pr after fake pr hitting my e feed as I type this"
Are you able to provide proof that the PR's are fake? All is it all in you opinion?